Terzepatide

Unassigned

New Medicines

Type 2 diabetes mellitus

Information

New molecular entity
Eli Lilly
Eli Lilly

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Dual glucose-dependent insulinotropic peptide (GIP) and GLP-1 receptor agonist (first in class)
The increasing prevalence of diabetes worldwide has led to a situation where approximately 360 million people had diabetes in 2011, of whom more than 95% would have had type 2 diabetes. This number is estimated to increase to 552 million by 2030 and it is thought that about half of those will be unaware of their diagnosis [1].
Type 2 diabetes mellitus
Subcutaneous injection